Cargando…
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In th...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850884/ https://www.ncbi.nlm.nih.gov/pubmed/20226010 http://dx.doi.org/10.1186/1476-4598-9-57 |
_version_ | 1782179814016286720 |
---|---|
author | Roulin, Didier Cerantola, Yannick Dormond-Meuwly, Anne Demartines, Nicolas Dormond, Olivier |
author_facet | Roulin, Didier Cerantola, Yannick Dormond-Meuwly, Anne Demartines, Nicolas Dormond, Olivier |
author_sort | Roulin, Didier |
collection | PubMed |
description | The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In this study, we explored the specific role of mTORC2 in colon cancer using a short hairpin RNA expression system to silence the mTORC2-associated protein rictor. We found that downregulation of rictor in HT29 and LS174T colon cancer cells significantly reduced cell proliferation. Knockdown of rictor also resulted in a G1 arrest as observed by cell cycle analysis. We further observed that LS174T cells deficient for rictor failed to form tumors in a nude mice xenograft model. Taken together, these results show that the inhibition of mTORC2 reduces colon cancer cell proliferation in vitro and tumor xenograft formation in vivo. They also suggest that specifically targeting mTORC2 may provide a novel treatment strategy for colorectal cancer. |
format | Text |
id | pubmed-2850884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28508842010-04-08 Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo Roulin, Didier Cerantola, Yannick Dormond-Meuwly, Anne Demartines, Nicolas Dormond, Olivier Mol Cancer Short communication The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In this study, we explored the specific role of mTORC2 in colon cancer using a short hairpin RNA expression system to silence the mTORC2-associated protein rictor. We found that downregulation of rictor in HT29 and LS174T colon cancer cells significantly reduced cell proliferation. Knockdown of rictor also resulted in a G1 arrest as observed by cell cycle analysis. We further observed that LS174T cells deficient for rictor failed to form tumors in a nude mice xenograft model. Taken together, these results show that the inhibition of mTORC2 reduces colon cancer cell proliferation in vitro and tumor xenograft formation in vivo. They also suggest that specifically targeting mTORC2 may provide a novel treatment strategy for colorectal cancer. BioMed Central 2010-03-12 /pmc/articles/PMC2850884/ /pubmed/20226010 http://dx.doi.org/10.1186/1476-4598-9-57 Text en Copyright ©2010 Roulin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short communication Roulin, Didier Cerantola, Yannick Dormond-Meuwly, Anne Demartines, Nicolas Dormond, Olivier Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
title | Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
title_full | Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
title_fullStr | Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
title_full_unstemmed | Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
title_short | Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
title_sort | targeting mtorc2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo |
topic | Short communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850884/ https://www.ncbi.nlm.nih.gov/pubmed/20226010 http://dx.doi.org/10.1186/1476-4598-9-57 |
work_keys_str_mv | AT roulindidier targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo AT cerantolayannick targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo AT dormondmeuwlyanne targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo AT demartinesnicolas targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo AT dormondolivier targetingmtorc2inhibitscoloncancercellproliferationinvitroandtumorformationinvivo |